צמיחת רווחי EPS רבעונית Vanda Pharmaceuticals (VNDA)
Vanda Pharmaceuticals (VNDA) relies on exclusive patents in psychopharmacology, allowing for flexible pricing power over orphan drugs. The quarter-over-quarter EPS dynamics provided by GURU.Markets demonstrate the current metric 2.30. Stable cash flow from mature products and adherence to ESG standards in bio-development create a solid foundation for the company's long-term growth.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_VNDA_-_Vanda-Pharmaceuticals_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווחי EPS רבעונית vandapharma.com (VNDA): לתקופה 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Vanda (VNDA)
Vanda Pharmaceuticals (VNDA) occupies the niche of a developer of targeted drugs for the therapy of CNS disorders, leveraging robust R&D potential. Earnings per share dynamics reflect the efficiency of monetizing these innovations and the company's ability to create shareholder value. By analyzing the intensity of quarterly EPS growth, investors assess the rate of net income increase relative to market expectations. A positive trend confirms financial stability and the potential for payouts. The stability of this metric testifies to the fundamental strength of the biopharmaceutical business.
